Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $13,875.85 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Daan Van sold 2,861 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $4.85, for a total transaction of $13,875.85. Following the sale, the insider owned 350,808 shares in the company, valued at approximately $1,701,418.80. This trade represents a 0.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Thursday, April 9th, Well Daan Van sold 1,988 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,423.12.
• On Monday, April 6th, Well Daan Van sold 2,705 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $13,146.30.
• On Thursday, March 19th, Well Daan Van sold 684 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $3,276.36.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH opened at $4.70 on Monday. SOPHiA GENETICS SA has a 1 year low of $2.58 and a 1 year high of $5.70. The firm’s 50 day moving average price is $4.75 and its 200 day moving average price is $4.70. The firm has a market cap of $321.90 million, a P/E ratio of -9.22 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The firm had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. As a group, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of large investors have recently bought and sold shares of the stock. Green Alpha Advisors LLC raised its stake in SOPHiA GENETICS by 10.8% during the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after purchasing an additional 4,444 shares during the period. Dimensional Fund Advisors LP raised its stake in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the period. Savvy Advisors Inc. purchased a new position in SOPHiA GENETICS during the third quarter worth approximately $48,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS in the third quarter worth $49,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter worth $49,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on SOPH. BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Guggenheim increased their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.